Crossmark

Clonal evolution in chronic lymphocytic leukemia is associated with an unmutated IGHV status and frequently leads to a combination of loss of TP53 and TP53 mutation

Crossref DOI link: https://doi.org/10.1007/s11033-022-07888-y

Published Online: 2022-09-28

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bracher, Susanne

Fuhrmann, Irene

Jeromin, Sabine

Nadarajah, Niroshan

Kern, Wolfgang

Haferlach, Torsten

Haferlach, Claudia

Stengel, Anna
License Information

Text and Data Mining valid from 2022-09-28

Version of Record valid from 2022-09-28
More Information

Article History

Received: 6 July 2022

Revised: 12 August 2022

Accepted: 18 August 2022

First Online: 28 September 2022

Declarations

:

: CH, WK, and TH declare part ownership of Munich Leukemia Laboratory (MLL). SB, IF, SJ, NN, and AS are employed by the MLL.

: All patients had given a written informed consent, to the use of laboratory data according to the Declaration of Helsinki. The study was conducted in accordance with the Declaration of Helsinki and the Ethics Committee of the Bavarian State Medical Association.

: Informed consent was obtained from all individual participants included in the study.

Document is current

Any future updates will be listed below